Cancer diagnosis & prognosis最新文献

{"title":"Chemotherapy in Combination With Methionine Restriction Induced A Complete Response in a Patient With Recurrent Metastatic Tongue Squamous-Cell Carcinoma.","authors":"Tomoyuki Ishiguro, Toshihiko Sato, Qinghong Han, Shukuan Li, Yuta Miyashi, Byung Mo Kang, Jin Soo Kim, Takuya Tsunoda, Robert M Hoffman","doi":"10.21873/cdp.10542","DOIUrl":"10.21873/cdp.10542","url":null,"abstract":"<p><strong>Background/aim: </strong>Recurrent head and neck squamous-cell carcinoma (HNSCC) is associated with poor prognosis and limited treatment options, particularly after failure of standard therapies including surgery, radiotherapy, chemotherapy, and immune checkpoint inhibitors. Methionine restriction has emerged as a novel clinical metabolic therapeutic strategy targeting the methionine addiction of cancer cells. The present patient report describes a case of recurrent tongue HNSCC that achieved complete remission with chemotherapy combined with methionine restriction.</p><p><strong>Case report: </strong>A 35-year-old man was diagnosed with HNSCC of the left lateral border of the tongue (cT2N2bM0, Stage IVA). The patient underwent curative-intent surgery consisting of partial glossectomy and neck dissection. Despite multimodal treatment, including induction chemotherapy, salvage surgery, postoperative chemoradiotherapy, and subsequent immune checkpoint inhibitor therapy, the tumor recurred in the left submandibular region. Following further progression, combination chemotherapy with paclitaxel and cetuximab was administered in combination with methionine restriction (MR), consisting of a low-methionine diet and oral recombinant methioninase (rMETase), rMETase was produced using recombinant <i>Escherichia coli</i> expressing the <i>methioninase</i> gene from <i>Pseudomonas putida</i> and purified by standard methods. Tumor metabolic activity was evaluated using [¹⁸F]fluorodeoxyglucose positron-emission tomography (PET)/computed tomography (CT) performed according to standard clinical protocols. Rapid tumor regression was observed. Follow-up magnetic resonance imaging (MRI) and PET/CT demonstrated complete response, which was maintained after de-escalation to cetuximab combined with MR.</p><p><strong>Conclusion: </strong>The present case demonstrates the potential clinical efficacy of combining chemotherapy with MR in the treatment of recurrent HNSCC after curative-intent surgery and failure of standard therapies, including immune checkpoint inhibition. MR may represent a promising metabolic therapeutic approach for refractory HNSCC. Αdditional cases and prospective clinical trials are necessary.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"6 3","pages":"428-433"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13133832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GRIm Score Predicts Curative Conversion Surgery in Unresectable Gastric Cancer.","authors":"Tomoyuki Nagata, Sae Morishita, Yuya Arimura, Haruka Fujimoto, Masahiro Kojo, Kenichi Takemoto, Yayoi Kadotani, Kei Naito, Katsunori Nakano","doi":"10.21873/cdp.10545","DOIUrl":"10.21873/cdp.10545","url":null,"abstract":"<p><strong>Background/aim: </strong>Conversion surgery can prolong survival in initially unresectable gastric cancer when curative (R0) resection is achieved; however, pre-treatment predictors of R0 conversion remain limited. We investigated whether the Gustave Roussy Immune (GRIm) score predicts R0 resection and survival in patients considered for conversion surgery.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed 57 patients with unresectable advanced gastric cancer treated with systemic chemotherapy from January 2019 to July 2025. Patients were classified as achieving conversion (AC; conversion surgery with R0 resection) or non-conversion (NC). The GRIm score (albumin, lactate dehydrogenase, and neutrophil-to-lymphocyte ratio) and clinicopathological variables were evaluated as predictors of R0 resection using univariate and multivariate logistic regression. Overall survival (OS) was assessed using the Kaplan-Meier method.</p><p><strong>Results: </strong>Ten patients (17.5%) achieved R0 resection. The AC group had lower GRIm scores and a more favorable Yoshida classification than the NC group, and intestinal-type histology was more frequent in the AC group. In multivariate analysis, a low GRIm score (0-1) and Yoshida classification C1-2 were independently associated with R0 resection. OS was significantly longer in patients with low GRIm scores than in those with high scores.</p><p><strong>Conclusion: </strong>The GRIm score is an accessible pre-treatment biomarker associated with successful R0 conversion surgery and improved survival in unresectable gastric cancer and may complement the Yoshida classification in candidate selection.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"6 3","pages":"454-463"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13133802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Quality of Life and Risk Factors in Patients With Covert Hepatic Encephalopathy Including Those With Hepatocellular Carcinoma.","authors":"Toru Ishikawa, Riho Ito, Narumi Arita, Yusuke Matsuhashi, Terasu Honma","doi":"10.21873/cdp.10553","DOIUrl":"10.21873/cdp.10553","url":null,"abstract":"<p><strong>Background/aim: </strong>Covert hepatic encephalopathy (CHE) is associated with a decline in quality of life (QOL), requiring early detection and intervention. We aimed to determine CHE prevalence, QOL correlations, and risk factors in hospitalized patients with cirrhosis. This study evaluated neuropsychological test (NPT) results and QOL in these patients.</p><p><strong>Patients and methods: </strong>This retrospective study included 56 patients with liver cirrhosis who were hospitalized at our institution from January to November 2024 and underwent simultaneous short form health survey (SF-36) testing and NPT. The NPT included the number connection (NCT)-A and Stroop tests. QOL was assessed using the SF-36, and risk factors evaluated using hematological data at admission.</p><p><strong>Results: </strong>The mean patient age was 67.5 years, with 39 men and 17 women. Hepatocellular carcinoma was observed in 35 patients (63%). Underlying liver diseases were: hepatitis C virus in seven patients, hepatitis B virus in four, alcohol damage in 16, metabolic dysfunction-associated steatohepatitis in 10, autoimmune hepatitis in four, and others in 15. CHE was detected in 24 patients (43%): three (13%) with abnormal NCT-A findings, 14 (58%) with abnormal Stroop findings, and seven (29%) with both abnormalities. On SF-36 assessment, patients with CHE had significantly lower role-physical (RP) scores than those without CHE [30.80 (2.55-55.72) <i>vs</i>. 49.07 (12.52-55.72), <i>p</i>=0.022]. Furthermore, role-emotion and vitality tended to be lower in patients with CHE. Patients with CHE also had significantly lower Zn levels than those without [67 (42-110) <i>vs</i>. 81 (44-190); <i>p</i>=0.016].</p><p><strong>Conclusion: </strong>Patients with CHE experienced reduced QOL RP and low Zn levels, suggesting that early Zn supplementation may improve CHE and enhance QOL.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"6 3","pages":"537-543"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13133852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Predictors and Long-term Outcomes of Non-benign Breast Phyllodes Tumors.","authors":"Emi Tsukiyama, Akira Matsui, Hirohito Seki, Erina Odani, Marika Sato, Hinako Tezuka, Yuya Murata, Takayuki Kinoshita","doi":"10.21873/cdp.10547","DOIUrl":"10.21873/cdp.10547","url":null,"abstract":"<p><strong>Background/aim: </strong>Phyllodes tumors of the breast are rare fibroepithelial neoplasms with heterogeneous biological behavior. Reliable preoperative predictors of non-Benign (borderline and malignant) tumors remain incompletely defined. This study aimed to identify clinical predictors of non-Benign phyllodes tumors and to evaluate long-term outcomes.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed 106 patients who underwent surgical resection for breast phyllodes tumors at a single institution. Tumors were classified as benign, borderline, or malignant according to World Health Organization criteria. The presence of rapid tumor growth was determined based on clinical records. Univariate and multivariate logistic regression analyses were performed to identify predictors of non-Benign tumors. Local recurrence-free survival was assessed using long-term follow-up data.</p><p><strong>Results: </strong>Of the 106 tumors, 54 were benign, 46 borderline, and 6 malignant. The median follow-up period was 109 months. In univariate analysis, age and the presence of rapid tumor growth were significantly associated with non-Benign tumors. Multivariate analysis demonstrated that both age and the presence of rapid tumor growth were independent predictors of non-Benign phyllodes tumors. Tumor size and preoperative diagnosis were not independently associated with non-Benign tumors. Only one case (0.9%) of local recurrence was observed, and no distant metastases occurred during follow-up.</p><p><strong>Conclusion: </strong>Breast phyllodes tumors have an excellent long-term prognosis with a very low risk of recurrence. Age and the presence of rapid tumor growth are useful clinical indicators for predicting non-Benign phyllodes tumors and may aid in preoperative assessment and clinical decision-making.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"6 3","pages":"472-478"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13133865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristic Clinical Features of Melanoma in Patients With Excised Skin Lesions.","authors":"Oliwia Majewska, Piotr Kulig, Paweł Brzewski, Jan Kulig, Anna Markiewicz","doi":"10.21873/cdp.10540","DOIUrl":"10.21873/cdp.10540","url":null,"abstract":"<p><strong>Background/aim: </strong>The aim of this study was to assess the risk of melanoma in patients with excised skin lesions (ESLs) considering their clinical features.</p><p><strong>Patients and methods: </strong>A total of 126 cases of ESLs were collected between December 2021 and April 2025. The clinical features of 109 benign skin lesions (BSLs), 10 non-nodular melanomas (NNMs), and seven nodular melanomas (NMs) were analyzed according to the ABCDE criteria, the ABCDE-EFG method, and the 7-point checklist (7-PCL) scale.</p><p><strong>Results: </strong>In univariate analysis, compared to BSLs, NNMs presented more common irregular borders (<i>p</i>=0.029), color variegation (<i>p</i>=0.015), diameter greater than 6 mm (<i>p</i>=0.031), evolution in size, shape or color within six months (<i>p</i>=0.005), rapid growth within six weeks/atypical skin lesion <i>de novo</i> (<i>p</i>=0.019). NMs, compared to BSLs, were more likely to show evolution in size, shape or color within six months (<i>p</i>=0.003), elevation (<i>p</i>=0.003), firm to touch (<i>p</i><0.001), and rapid growth within six weeks/atypical skin lesion <i>de novo</i> (<i>p</i><0.001). In the Firth's penalized logistic regression, rapid growth within six weeks/atypical skin lesion <i>de novo</i> was significantly more frequent in NNMs compared to BSLs [odds ratio (OR)=31.36, 95% confidence interval (CI)=1.42-11350.06, <i>p=</i>0.028], and in both NNMs and NMs compared to BSLs (OR=27.32, 95% CI=3.64-540.48, <i>p</i><0.001). Color variegation (OR=25.06, 95% CI=2.80-681.62, <i>p</i>=0.002) and evolution in size, shape or color within six months (OR=6.02, 95% CI=1.21-55.19, <i>p</i>=0.027) were also found to be significant in differentiating for both NNMs and NMs compared to BSLs. However, in multivariate analysis, for NMs alone, no clinical features were significantly more frequent compared to BSLs.</p><p><strong>Conclusion: </strong>The most important clinical features increasing the risk of melanoma were rapid growth within six weeks/atypical skin lesion <i>de novo</i>, color variegation and evolution in size, shape or color within six months, but not for NMs cases alone in the Firth's penalized logistic regression.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"6 3","pages":"408-418"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13133750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of Carcinoembryonic Antigen Levels After Chemoradiotherapy for Advanced Low Rectal Cancer.","authors":"Atsushi Tsuruta, Kazuhiko Yoshimatsu, Tomio Ueno","doi":"10.21873/cdp.10551","DOIUrl":"10.21873/cdp.10551","url":null,"abstract":"<p><strong>Background/aim: </strong>Preoperative chemoradiotherapy (CRT) followed by total mesorectal excision is the standard treatment for advanced low rectal cancer; however, long-term oncological outcomes vary widely, and reliable prognostic biomarkers remain limited. Carcinoembryonic antigen (CEA) is commonly used in colorectal cancer management, but the prognostic value of post-CRT CEA levels has not been fully clarified. This study aimed to identify clinically relevant prognostic factors for recurrence and survival, with particular focus on pre- and post-CRT CEA levels.</p><p><strong>Patients and methods: </strong>A retrospective review was conducted of 41 consecutive patients with advanced low rectal cancer (Rb, cT3/4 or N1/2 and no lateral lymph node metastasis) who underwent long-course preoperative CRT followed by radical surgery. CRT consisted of 45 Gy in 25 fractions with concurrent tegafur/uracil, followed by total mesorectal excision 8-10 weeks after CRT completion. Clinicopathological factors were analyzed in relation to recurrence, disease-free survival (DFS), and overall survival (OS).</p><p><strong>Results: </strong>With a median follow-up of 69.3 months, recurrence occurred in 16 patients. Five-year DFS and OS rates were 59.4% and 73.2%, respectively. Univariate analysis identified postoperative complications, pathological complete response, and pre- and post-CRT CEA levels as significant factors associated with recurrence. Multivariate analysis demonstrated that post-CRT CEA was the only independent prognostic factor. Receiver operating characteristic analysis identified a post-CRT CEA cut-off value of 3.9 ng/ml. Patients with lower post-CRT CEA showed significantly better DFS and OS.</p><p><strong>Conclusion: </strong>Post-CRT CEA is a valuable prognostic biomarker for recurrence and survival in advanced low rectal cancer, and patients with elevated post-CRT CEA may benefit from additional consolidation chemotherapy.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"6 3","pages":"510-519"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13133762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Protein Tyrosine Phosphatase Kappa Expression Is Associated With Disease Progression and Poor Prognosis of Pancreatic Cancer.","authors":"Ziqian Fang, Xiangyi Liu, Xiuyun Tian, Bilal Al-Sarireh, Chunyi Hao, Wen G Jiang, Lin Ye","doi":"10.21873/cdp.10560","DOIUrl":"10.21873/cdp.10560","url":null,"abstract":"<p><strong>Background/aim: </strong>Protein tyrosine phosphatase kappa (PTPRK), a recognized tumor suppressor, has been implicated in cancer progression of certain solid tumors. This study investigated the role of PTPRK in the progression of pancreatic cancer.</p><p><strong>Materials and methods: </strong>PTPRK transcripts were determined in a pancreatic cancer cohort using real-time PCR. The functional impact of PTPRK was evaluated in pancreatic cancer cells with PTPRK knockdown, followed by an assessment of its implications in disease progression.</p><p><strong>Results: </strong>Elevated PTPRK expression was observed in pancreatic cancer and was positively correlated with tumor T stage. Knockdown of PTPRK led to reduced cellular proliferation and decreased expression of cyclin-dependent kinase 6 (CDK6). Additionally, an increase in VEGFC expression was noted in PTPRK knockdown cells.</p><p><strong>Conclusion: </strong>Up-regulation of PTPRK in pancreatic cancer is associated with disease progression and poor prognosis. PTPRK facilitates cancer cell proliferation through CDK6, highlighting the potential for therapeutic strategies targeting PTPRK and CDK6 in pancreatic cancer treatment.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"6 3","pages":"596-607"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13133845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Combination of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 and Recombinant Methioninase Is Not Cancer-selective in a Co-culture Model of Colon Cancer Cells and Normal Fibroblasts.","authors":"Jinsoo Kim, Qinghong Han, Shukuan Li, Byung Mo Kang, Kohei Mizuta, Yohei Asano, Yuta Miyashi, Michael Bouvet, Robert M Hoffman","doi":"10.21873/cdp.10559","DOIUrl":"10.21873/cdp.10559","url":null,"abstract":"<p><strong>Background/aim: </strong>Methionine addiction is a fundamental and general hallmark of cancer cells. Recombinant <i>methioninase</i> (rMETase) degrades extracellular methionine. rMETase, or other means of restricting methionine, in combination with numerous types of chemotherapy have shown synergistic cancer-selective efficacy. AG-270, a methionine adenosyltransferase 2A (MAT2A) inhibitor, blocks intracellular conversion of methionine to S-adenosylmethionine (SAM), the central reaction of the methionine cycle. The present study aimed to evaluate the synergistic and cancer-selective efficacy of the combination of AG-270 and rMETase in a co-culture model of cancer and normal cells.</p><p><strong>Materials and methods: </strong>HCT116 human colon-cancer cells expressing green fluorescent protein (GFP) and human Hs-27 normal fibroblasts were co-cultured in Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal bovine serum in 12-well plates. Co-cultures were treated with AG-270 (6 μM and 10 µM) and rMETase (0.3 U/ml and 0.5 U/ml) alone or in combination. Cell growth and viability were assessed by phase-contrast microscopy and fluorescence  imaging over 6 days.</p><p><strong>Results: </strong>Treatment with AG-270 or rMETase alone inhibited HCT116 colon-cancer cell viability in a dose-dependent manner, whereas Hs-27 normal fibroblasts remained viable on day 6 in co-culture. In contrast, the combination of AG-270 and rMETase produced a strong, synergistic reduction of the viability of both HCT116 and Hs-27 cells, accompanied by extensive morphological damage, in co-culture. GFP-expressing HCT116 colon-cancer cells were nearly eradicated by the combination treatment, as visualized by fluorescence imaging on day 6 in co-culture with Hs-27 fibroblasts.</p><p><strong>Conclusion: </strong>Dual inhibition of methionine metabolism by AG-270 and rMETase was toxic to both cancer cells and normal fibroblasts in a co-culture model which is internally controlled. In contrast, rMETase combined with numerous first-line chemotherapeutic drugs acted selectively and synergistically against cancer cells while sparing normal cells, including co-culture models. The present results suggest that AG-270 may have limited potential as an anticancer agent.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"6 3","pages":"586-595"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13133766/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Hyalinizing Clear-cell Carcinoma With <i>EWSR1-ATF1</i> Fusion Gene Arising From the Minor Salivary Gland of the Tongue.","authors":"Kaname Sakuma, Haruka Takahashi, Daichi Hanada, Yosuke Kikuchi, Junya Ono, Shuji Toya, Yasuo Okada, Akira Tanaka","doi":"10.21873/cdp.10558","DOIUrl":"10.21873/cdp.10558","url":null,"abstract":"<p><strong>Background/aim: </strong>Hyalinizing clear-cell carcinoma (HCCC) is a rare malignant tumor of the minor salivary glands characterized by nests of clear cells within a hyalinized stroma. Its diagnosis remains challenging due to its histological similarity to other neoplasms, and the recent recognition of distinct molecular features, such as Ewing sarcoma breakpoint region 1 (<i>EWSR1)</i>-activating transcription factor 1 (<i>ATF1</i>) fusion. This report describes a rare case of HCCC arising from the tongue with confirmed <i>EWSR1-ATF1</i> fusion.</p><p><strong>Case report: </strong>A 54-year-old man presented with a painless mass on the right lateral border of the tongue. Clinical examination revealed an elastic hard tumor measuring 18×15×8 mm. Biopsy under local anesthesia revealed a malignant clear-cell neoplasm. The lesion was completely excised under general anesthesia 2 weeks later. Histopathology showed nests of clear cells with polygonal nuclei in a hyalinized stroma. Immunohistochemistry demonstrated positivity for cytokeratin AE1/AE3, p63 protein and cytokeratin 7, and negativity for cytokeratin 20, <i>α</i>-smooth muscle actin, S-100 protein, vimentin, and cluster of differentiation 10. Periodic acid-Schiff staining was positive, with no diastase sensitivity. Fluorescence <i>in situ</i> hybridization revealed <i>EWSR1</i> rearrangement, confirmed by reverse transcription-polymerase chain reaction as an <i>EWSR1-ATF1</i> fusion. Perifocal stroma showed marked hyalinization. These findings support a diagnosis of HCCC with hyalinization. The patient remained disease-free 5 years after surgery.</p><p><strong>Conclusion: </strong>This case highlights the diagnostic importance of integrating histopathology, immunoprofiling, and molecular analysis in patients with rare salivary gland tumors and underscores the favorable outcomes of complete surgical resection for HCCC of the tongue.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"6 3","pages":"579-585"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13133831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare Case of Appendiceal Gastrointestinal Stromal Tumor: Diagnosis, Surgical Management, and Long-term Outcome.","authors":"Michi Ueno, Kazuhiko Yoshimatsu, Shuya Yano, Atsushi Tsuruta, Yuko Okamoto, Shuji Kitagawa, Masaharu Higashida, Toshimasa Okada, Shunji Endo, Yoshinori Fujiwara, Tomio Ueno","doi":"10.21873/cdp.10554","DOIUrl":"10.21873/cdp.10554","url":null,"abstract":"<p><strong>Background/aim: </strong>Appendiceal gastrointestinal stromal tumors (GISTs) are exceptionally rare neoplasms.</p><p><strong>Case report: </strong>We report a case of a 68-year-old man who presented with recurrent right lower quadrant abdominal pain. Ultrasonography revealed a 10×4 mm hypoechoic submucosal tumor adjacent to the appendiceal orifice. Contrast-enhanced computed tomography demonstrated a delayed-enhancing appendiceal lesion without regional lymphadenopathy. Laparoscopic appendectomy was performed. Histopathological examination revealed an 8-mm tumor composed of spindle-shaped cells arising from the muscularis propria of the appendix. Immunohistochemical analysis showed positivity for c-kit and CD34, leading to a diagnosis of very low-risk appendiceal GIST.</p><p><strong>Conclusion: </strong>This case highlights the diagnostic challenges posed by this extremely rare entity and contributes additional long-term outcome data to the limited literature on appendiceal GISTs. Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, most frequently arising in the stomach (approximately 60%) and small intestine (approximately 30%) (1). In contrast, GISTs originating from the appendix are exceedingly rare, accounting for approximately 0.1% of all GISTs (2). Owing to their rarity and small size, appendiceal GISTs are often discovered incidentally and may present diagnostic challenges. Herein, we report a rare case of appendiceal GIST detected preoperatively and successfully treated by laparoscopic appendectomy, with long-term recurrence-free survival.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"6 3","pages":"544-547"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13133807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}